Guillermo Robles - DIAGNOS President
President
Mr. Guillermo Moreno Robles was appointed as Vice President Health Care Business Development of Latin America of the Company. Mr. Robles joined the company in 2014. Over the past two years, he was a key asset in the development of the health care activities in Mexico and Colombia. since 2016.
| Tenure | 8 years |
| Phone | 450 678 8882 |
| Web | https://www.diagnos.ca |
DIAGNOS Management Efficiency
The company has return on total asset (ROA) of (1.2131) % which means that it has lost $1.2131 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (24.5157) %, meaning that it generated substantial loss on money invested by shareholders. DIAGNOS's management efficiency ratios could be used to measure how well DIAGNOS manages its routine affairs as well as how well it operates its assets and liabilities.DIAGNOS has accumulated 831.58 K in total debt with debt to equity ratio (D/E) of 2.45, implying the company greatly relies on financing operations through barrowing. DIAGNOS has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist DIAGNOS until it has trouble settling it off, either with new capital or with free cash flow. So, DIAGNOS's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DIAGNOS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DIAGNOS to invest in growth at high rates of return. When we think about DIAGNOS's use of debt, we should always consider it together with cash and equity.
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company was founded in 1998 and is headquartered in Brossard, Canada. Diagnos operates under Health Information Services classification in the United States and is traded on OTC Exchange. DIAGNOS [DGNOF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Management Performance
| Return On Equity | -24.52 | |||
| Return On Asset | -1.21 |
DIAGNOS Leadership Team
Elected by the shareholders, the DIAGNOS's board of directors comprises two types of representatives: DIAGNOS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DIAGNOS. The board's role is to monitor DIAGNOS's management team and ensure that shareholders' interests are well served. DIAGNOS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DIAGNOS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Beland, Director Marketing | ||
| Guillermo Robles, Vice President - Health Care Business Development of Latin America | ||
| MarcAndr Massue, CFO Fin | ||
| Andre Larente, CEO and President and Executive Director |
DIAGNOS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is DIAGNOS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -24.52 | |||
| Return On Asset | -1.21 | |||
| Operating Margin | (4.06) % | |||
| Current Valuation | 12.4 M | |||
| Shares Outstanding | 69.47 M | |||
| Shares Owned By Insiders | 16.34 % | |||
| Price To Earning | (4.08) X | |||
| Price To Book | 55.55 X | |||
| Price To Sales | 16.90 X | |||
| Revenue | 438.83 K |
Currently Active Assets on Macroaxis
Other Information on Investing in DIAGNOS OTC Stock
DIAGNOS financial ratios help investors to determine whether DIAGNOS OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DIAGNOS with respect to the benefits of owning DIAGNOS security.